Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease

Brazilian Journal of Medical and Biological Research

Volumn 41, Issue 10, 2008, Pages 926-931

  Nunes, D M ^a   Mota, R M S ^a   Machado, M O ^a   Pereira, E D B ^a   de Bruin, V M S ^a   de Bruin, P Felipe C ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Chronic obstructive pulmonary disease; Melatonin; Sleep

Indexed keywords

MELATONIN; PLACEBO;

ADULT; AGED; BEDTIME DOSAGE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; EPWORTH SLEEPINESS SCALE; EXERCISE; FEMALE; HUMAN; LUNG FUNCTION; MALE; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; SLEEP DISORDER; SPIROMETRY; WALKING; XEROSTOMIA;

EID: 59849084167     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2008001000016     Document Type: Conference Paper

References (40)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
2. Mannino DM, Holguin F. Epidemiology and global impact of chronic obstructive pulmonary disease. Respir Med: COPD Update 2006; 1: 114-120.
3. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875-1881.
4. Weitzenblum E, Chaouat A. Sleep and chronic obstructive pulmonary disease. Sleep Med Rev 2004; 8: 281-294.
5. Santos CEVG, Viegas CAA. Sleep pattern in patients with chronic obstructive pulmonary disease and correlation among gasometric, spirometric, and polysomnographic variables. J Pneumol 2003; 29: 69-74.
6. McNicholas WT. Sleep in chronic obstructive pulmonary disease. Eur Respir Mon 2006; 38: 325-336. [http://www.maney.co.uk/series/ers]
7. Breslin E, van der Schans C, Breukink S, Meek P, Mercer K, Volz W, et al. Perception of fatigue and quality of life in patients with COPD. Chest 1998; 114: 958-964.
8. Phillips BA, Cooper KR, Burke TV. The effect of sleep loss on breathing in chronic obstructive pulmonary disease. Chest 1987; 91: 29-32.
9. Kutty K. Sleep and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2004; 10: 104-112.
10. Scheer FA, Czeisler CA. Melatonin, sleep, and circadian rhythms. Sleep Med Rev 2005; 9: 5-9.
11. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24.
12. Campos FL, da Silva-Junior FP, de Bruin V, de Bruin PF. Melatonin improves sleep in asthma: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2004; 170: 947-951.
13. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magalhaes MC, de Lourdes SM, de Bruin V. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol 2007; 254: 459-464.
14. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9: 41-50.
15. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006; 332: 385-393.
16. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
17. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540-545.
18. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 16: 111-117.
19. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
20. Norusis MJ. SPSS for Windows: Base System User's Guide. Release 15.0. [Computer program]. 2006.
21. Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, et al. Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study. Chronobiol Int 2000; 17: 71-76.
22. Pires ML, Benedito-Silva AA, Pinto L, Souza L, Vismari L, Calil HM. Acute effects of low doses of melatonin on the sleep of young healthy subjects. J Pineal Res 2001; 31: 326-332.
23. Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR, Dollins AB, Morabito C, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995; 57: 552-558.
24. Cajochen C, Krauchi K, Danilenko KV, Wirz-Jústice A. Evening administration of melatonin and bright light: interactions on the EEG during sleep and wakefulness. J Sleep Res 1998; 7: 145-157.
25. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998; 21: 52-68.
26. Dawson D, Rogers NL, van den Heuvel CJ, Kennaway DJ, Lushington K. Effect of sustained nocturnal transbuccal melatonin administration on sleep and temperature in elderly insomniacs. J Biol Rhythms 1998; 13: 532-538.
27. Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology 1990; 100: 222-226.
28. Arendt J. Importance and relevance of melatonin to human biological rhythms. J Neuroendocrinol 2003; 15: 427-431.
29. Tenn CC, Niles LP. Central-type benzodiazepine receptors mediate the antidopaminergic effect of clonazepam and melatonin in 6-hydroxydopamine lesioned rats: involvement of a GABAergic mechanism. J Pharmacol Exp Ther 1995; 274: 84-89.
30. Nave R, Herer P, Haimov I, Shlitner A, Lavie P. Hypnotic and hypothermic effects of melatonin on daytime sleep in humans: lack of antagonism by flumazenil. Neurosci Lett 1996; 214: 123-126.
31. Zhdanova IV, Raz DJ. Effects of melatonin ingestion on cAMP and cGMP levels in human plasma. J Endocrinol 1999; 163: 457-462.
32. Edgar DM, Dement WC, Fuller CA. Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J Neurosci 1993; 13: 1065-1079.
33. Dijk DJ, Czeisler CA. Paradoxical timing of the circadian rhythm of sleep propensity serves to consolidate sleep and wakefulness in humans. Neurosci Lett 1994; 166: 63-68.
34. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997; 19: 91-102.
35. Cormick W, Olson LG, Hensley MJ, Saunders NA. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax 1986; 41: 846-854.
36. Orr WC, Shamma-Othman Z, Levin D, Othman J, Rundell OH. Persistent hypoxemia and excessive daytime sleepiness in chronic obstructive pulmonary disease (COPD). Chest 1990; 97: 583-585.
37. Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med Rev 2005; 9: 51-65.
38. Rogers NL, Kennaway DJ, Dawson D. Neurobehavioural performance effects of daytime melatonin and temazepam administration. J Sleep Res 2003; 12: 207-212.
39. Luboshitzky R, Shen-Orr Z, Nave R, Lavi S, Lavie P. Melatonin administration alters semen quality in healthy men. J Androl 2002; 23: 572-578.
40. Armitage R, Trivedi M, Hoffmann R, Rush AJ. Relationship between objective and subjective sleep measures in depressed patients and healthy controls. Depress Anxiety 1997; 5: 97-102.